Table 3.
Comparison of the Baseline Characteristics of Patients with Early Compensated Cirrhosis who Received Transarterial Chemoembolization (TACE) versus Best Supportive Care (BSC)
| Characteristics | BSC (n=8) | TACE (n=31) | P value |
|---|---|---|---|
| Male sex | 5 (62.5%) | 23 (74.2%) | 0.663 |
| Age (years): mean ± SD | 58.8 ± 13.5 | 57.7 ± 10.7 | 0.812 |
| BMI (kg/m2): mean ± SD | 22.8 ± 4.6 | 24.2 ± 4.7 | 0.453 |
| Etiology of chronic liver disease | |||
| Hepatitis B infection | 4 (50.0%) | 9 (29.0%) | 0.402 |
| Hepatitis C infection | 0 (0%) | 12 (38.7%) | 0.042 |
| Alcohol-related liver disease | 1 (12.5%) | 11 (35.5%) | 0.394 |
| Portal hypertension | 4 (50%) | 24 (77.4%) | 0.012 |
| Laboratory data | |||
| Hemoglobin (g/dL): mean ± SD | 10.2 ± 1.7 | 11.7 ± 1.9 | 0.051 |
| Platelet median (x103/mL): median (IQR) | 198 (137.5 to 378.5) | 98 (69 to 178) | 0.022 |
| Serum creatinine (mg/dL): median (IQR) | 0.9 ± 0.2 | 0.9 ± 0.3 | 0.937 |
| Serum Albumin (g/dL): mean ± SD | 3.2 ± 0.8 | 3.0 ± 0.4 | 0.432 |
| Total bilirubin (mg/dL): median (IQR) | 1.8 (1.5 to 2.1) | 1.9 (1.1 to 2.7) | 0.626 |
| INR: mean ± SD | 1.1 ± 0.5 | 1.3 ± 0.2 | 0.275 |
| Alpha-fetoprotein (IU/mL): median (IQR) | 40.7 (2.0 to 187.2) | 20 (9.7 to 726.4) | 0.321 |
| Alpha-fetoprotein > 200 (IU/mL) | 2 (25.0%) | 12 (30.8%) | 0.686 |
| ECOG score | 0.049 | ||
| 0 | 2 (25.0%) | 21 (67.7%) | |
| 1 | 6 (75.0%) | 10 (25.7%) | |
| Multinodular | 8 (100%) | 23 (74.2%) | 0.168 |
| Tumor > 5 cm | 5 (62.5%) | 15 (48.4%) | 0.695 |
| Median longest tumor size (cm): median (IQR) | 7.0 (4.0 to 12.8) | 4.9 (3.5 to 9.5) | 0.186 |
Data are expressed as number (%) unless otherwise specified. BMI, body mass index; SD, standard deviation; INR, international normalized ratio; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group